Joseph R. Bertino

Joseph R. Bertino's AcademicInfluence.com Rankings

Joseph R. Bertino

Medical

#536

World Rank

#727

Historical Rank

#206

USA Rank

Pharmacology

#41

World Rank

#56

Historical Rank

#17

USA Rank

medical Degrees

Joseph R. Bertino

Philosophy

#2987

World Rank

#4930

Historical Rank

#997

USA Rank

Logic

#890

World Rank

#1456

Historical Rank

#309

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Joseph R. Bertino's Degrees

Doctorate Medicine University of Pennsylvania
PhD Pharmacology University of Pennsylvania

Why Is Joseph R. Bertino Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.

(See a Problem?)

Joseph R. Bertino's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prognostic effect of weight loss prior tochemotherapy in cancer patients (1980) (2049)
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. (1989) (1738)
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. (1990) (1040)
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. (1980) (951)
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. (1999) (865)
Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. (1978) (805)
A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance (2007) (428)
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation. (1997) (351)
Dihydrofolate reductase as a therapeutic target (1990) (343)
Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. (1995) (313)
Karnofsky memorial lecture. Ode to methotrexate. (1993) (298)
High dose cytosine arabinoside (HDARAC) in refractory acute leukemia (1979) (291)
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. (2009) (257)
Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. (2002) (248)
THE MECHANISM OF ACTION OF THE FOLATE ANTAGONISTS IN MAN. (1963) (240)
Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. (1969) (229)
p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. (1998) (226)
Potential regional differences for the tolerability profiles of fluoropyrimidines. (2008) (225)
MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics (2008) (212)
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells (2013) (211)
Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. (1992) (200)
Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. (1980) (195)
L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. (1971) (188)
Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. (1977) (184)
Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. (1997) (184)
Molecular Actions and Targets for Cancer Chemotherapeutic Agents (1981) (180)
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. (2001) (176)
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi‐mutated herpes simplex virus type‐1 (G207) (1999) (176)
Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. (1998) (174)
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. (2002) (167)
Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. (1991) (162)
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. (1994) (156)
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates (2013) (150)
Improved therapeutic index of methotrexate with "leucovorin rescue". (1973) (149)
Mechanisms of methotrexate resistance in osteosarcoma. (1999) (148)
STUDIES ON THE INHIBITION OF DIHYDROFOLATE REDUCTASE BY THE FOLATE ANTAGONISTS. (1964) (147)
Resistance to methotrexate due to gene amplification in a patient with acute leukemia. (1984) (146)
Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells (1979) (141)
24‐Hour infusion of cis‐platinum in head and neck cancers (1978) (140)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. (1998) (137)
Immunosuppressive effects of cytosine arabinoside and methotrexate in man. (1969) (133)
On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. (1981) (127)
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. (1998) (116)
Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". (1970) (115)
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity (2011) (115)
"Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. (1977) (115)
Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. (1995) (114)
Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. (1984) (113)
MiR-24 Tumor Suppressor Activity Is Regulated Independent of p53 and through a Target Site Polymorphism (2009) (112)
Phase II trial of paclitaxel in patients with soft-tissue sarcoma. (1998) (109)
Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. (1972) (109)
Purification and properties of carboxypeptidase G 1 . (1971) (107)
Quantitation of dihydrofolate reductase in individual parental and methotrexate-resistant murine cells. Use of a fluorescence activated cell sorter. (1978) (107)
Folate antagonists. (1967) (106)
Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. (1995) (106)
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. (2001) (103)
Chemotherapy of cancer of the head and neck (1973) (102)
Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. (2001) (100)
Discovery and clinical introduction of first-in-class imipridone ONC201 (2016) (100)
Long‐term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy (1975) (100)
Transport characteristics of folates in cerebrospinal fluid; a study utilizing doubly labeled 5-methyltetrahydrofolate and 5-formyltetrahydrofolate. (1971) (99)
PURIFICATION AND PROPERTIES OF DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS. (1965) (99)
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update (1994) (99)
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. (2001) (99)
Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture. (1979) (99)
Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. (1990) (97)
The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. (1991) (97)
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. (2000) (94)
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors (2017) (94)
Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. (1989) (94)
Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. (1988) (93)
THE "INDUCTION" OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN. (1963) (90)
STUDIES ON NORMAL AND LEUKEMIC LEUKOCYTES. IV. TETRAHYDROFOLATE-DEPENDENT ENZYME SYSTEMS AND DIHYDROFOLIC REDUCTASE. (1963) (88)
Role of E2F-1 in chemosensitivity. (1998) (88)
Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. (1993) (87)
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. (2003) (87)
Effective absorption and utilization of oral formyltetrahydrofolate in man. (1972) (86)
Combination sequential chemotherapy in advanced reticulum cell sarcoma (1972) (86)
Expression of bone morphogenetic proteins and receptors in sarcomas. (1999) (84)
Cancer research: from folate antagonism to molecular targets. (2009) (83)
Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. (1996) (83)
Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. (1997) (83)
Increased Level of Dihydrofolic Reductase in Leucocytes of Patients Treated with Amethopterin (1962) (83)
Amplification of dihydrofolate reductase genes in methotrexate-resistant cultured mouse cells. (1978) (83)
Cytotoxicity and Cell Growth Assays (2006) (82)
Regulation of thymidylate synthetase in mouse leukemia cells (L1210). (1980) (81)
ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. (2000) (80)
Long term remissions with combined modality therapy for advanced Hodgkin's disease (1976) (80)
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. (2002) (79)
Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines. (1985) (79)
Increased Photosensitivity in HL60 Cells Expressing Wild‐Type p53 (1997) (77)
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor--I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. (1979) (77)
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification and properties. (1967) (76)
7,8-Dihydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with purified dihydrofolate reductase from mammalian sources. (1974) (75)
METHOTREXATE DISPLACEMENT IN MAN. (1964) (75)
Uptake and Metabolism of N5-Formyltetrahydrofolate by L1210 Leukemia Cells (1972) (75)
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. (1993) (74)
S-phase cells of rapidly growing and resting populations. Differences in response to methotrexate. (1969) (74)
K-ras modulates the cell cycle via both positive and negative regulatory pathways (1997) (74)
Possible benefits of hyperthermia to chemotherapy. (1979) (73)
Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. (2013) (73)
Methotrexate therapy of Wegener's granulomatosis. (1971) (73)
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells (2015) (72)
TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. (1964) (72)
Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. (1986) (72)
Dependence of 5-methyltetrahydrofolate utilization by L5178Y murine leukemia cells in vitro on the presence of hydroxycobalamin and transcobalamin II. (1973) (71)
5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. (1980) (70)
Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma (2014) (69)
6-thioguanine: a drug with unrealized potential for cancer therapy. (2014) (69)
5-methyl-5,6,7,8-tetrahydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with methionine synthetase from bovine brain. (1975) (69)
Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. (2002) (68)
Enzymatic synthesis and function of folylpolyglutamates (1981) (68)
Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. (1989) (68)
Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. (1994) (68)
Enzymatic Cleavage of Methotrexate provides a Method for Prevention of Drug Toxicity (1972) (66)
Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. (1993) (66)
Functional roles of E2F in cell cycle regulation (1997) (64)
Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. (1992) (64)
Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression (2002) (63)
Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate. (1967) (63)
Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. (1977) (61)
Purification and properties of the formate-activating enzyme from erythrocytes. (1962) (61)
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers (2016) (61)
Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. (1989) (61)
Drug resistance in colon cancer. (1999) (60)
Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. (1983) (60)
Dihydrofolate reductase from the L1210R murine lymphoma. Fluorometric measurements of the interaction of the enzyme with coenzymes, substrates, and inhibitors. (1966) (59)
Detection of point mutations in human DNA by analysis of RNA conformation polymorphism(s). (1992) (59)
Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. (1992) (59)
The Journal of Clinical Oncology: The Initial Years (2008) (58)
Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. (1968) (58)
Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. (1991) (58)
Functional annotation of rare gene aberration drivers of pancreatic cancer (2016) (58)
Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. (2007) (57)
Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma (1990) (57)
Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. (1999) (57)
Overexpression of E2F-1 in Lung and Liver Metastases of Human Colon Cancer is Associated with Gene Amplification (2004) (56)
Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. (2003) (56)
Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells (2001) (55)
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction (1994) (55)
mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. (2003) (54)
Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development (2015) (53)
Trimetrexate: a second generation folate antagonist in clinical trial. (1987) (53)
Bleomycin therapy in advanced Hodgkin's disease and epidermoid cancers (1972) (53)
Carboxypeptidase G2 rescue after high-dose methotrexate. (1996) (53)
Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. (1978) (53)
Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. (1997) (53)
Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. (1999) (52)
Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. (1987) (52)
The relative toxicites of methotrexate and aminopterin. (1966) (52)
Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion (2014) (52)
Purification of mammalian tumor (L1210) thymidylate synthetase by affinity chromatography on stable biospecific adsorbent. Stabilization of the enzyme with neutral detergents. (1979) (51)
Lack of dihydrofolate reductase activity in brain tissue of mammalian species: possible implications 1 (1973) (51)
Development of a highly specific and sensitive molecular probe for detection of cutaneous lymphoma. (1991) (51)
The identity of rabbit-liver methotrexate oxidase. (1965) (51)
Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. (1987) (50)
Molecular mechanisms of resistance to antifolates, a review. (1995) (50)
Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. (1991) (50)
NAD+ Kinase as a Therapeutic Target in Cancer (2016) (49)
Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. (1983) (49)
Identification and characterization of a mutation in the dihydrofolate reductase gene from the methotrexate-resistant Chinese hamster ovary cell line Pro-3 MtxRIII. (1990) (49)
Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. (1995) (48)
Enzymatic synthesis of polyglutamate derivatives of 7-hydroxymethotrexate. (1984) (47)
Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man. (1973) (47)
Exploiting methionine restriction for cancer treatment. (2018) (47)
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. (1985) (47)
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer (2016) (47)
Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. (1998) (46)
Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. (1992) (45)
Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target (2012) (45)
Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. (1993) (45)
Curative potential of combined modality therapy for advanced Hodgkin's disease (1980) (45)
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment (2018) (45)
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance (2009) (44)
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. (1994) (44)
Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. (2001) (44)
Quantitation of Gene Copy Number and mRNA Using the Polymerase Chain Reaction (1992) (43)
Isolation and Characterization of Thymitaq (AG337) and 5-Fluoro-2-deoxyuridylate-resistant Mutants of Human Thymidylate Synthase from Ethyl Methanesulfonate-exposed Human Sarcoma HT1080 Cells* (1998) (43)
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. (1997) (43)
Reduced Folate Carrier and Dihydrofolate Reductase Expression in Acute Lymphocytic Leukemia May Predict Outcome: A Children's Cancer Group Study (2003) (42)
DNA-mediated gene transfer into epidermal cells using electroporation. (1986) (42)
"Induction" of dihydrofolate reductase: purification and properties of the "induced" human erythrocyte and leukocyte enzyme and normal bone marrow enzyme. (1970) (42)
Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). (1993) (42)
The turnover of folate coenzymes in murine lymphoma cells. (1973) (41)
Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma (2017) (41)
Separation of pteroyl-oligo-gamma-L-glutamates by high-performance liquid-chromatography. (1980) (40)
Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. (1986) (40)
Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? (2003) (40)
Effects of Overexpression of γ-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance (2001) (40)
Identification of Amino Acids Required for the Functional Up-regulation of Human Dihydrofolate Reductase Protein in Response to Antifolate Treatment* (2005) (39)
Role of methotrexate polyglutamates in methotrexate- and sequential methotrexate-5-fluorouracil-mediated cell kill. (1985) (39)
Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning (2019) (39)
Methylation of nucleic acids in normal and leukemic leukocytes. (1966) (39)
NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview (2020) (38)
Gene therapy utilizing drug resistance genes: A review (1994) (38)
Clinical pharmacology and metabolism of trimetrexate. (1988) (38)
Probing the Folate-binding Site of Human Thymidylate Synthase by Site-directed Mutagenesis (1998) (38)
Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. (1992) (37)
Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. (1991) (37)
Translational regulation of the synthesis of dihydrofolate reductase. (1993) (37)
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration (2019) (37)
Separation of substituted pteroyl monoglutamates and pteroyl oligo-gamma-L-glutamates by high pressure liquid chromatography. (1976) (36)
Intestinal folate absorption. II. Conversion and retention of pteroylmonoglutamate by jejunum. (1973) (36)
Sequential chemotherapy and radiotherapy. Preliminary results of clinical trial with methotrexate in head and neck cancer. (1966) (36)
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. (1998) (35)
Molecular and karyological analysis of methotrexate-resistant and -sensitive human leukemic CCRF-CEM cells. (1985) (35)
Imaging Colon Cancer Response Following Treatment with AZD1152: A Preclinical Analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]Fluorothymidine Imaging (2011) (35)
E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. (2006) (35)
Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma (1993) (35)
Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. (1969) (35)
gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. (1997) (34)
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. (1994) (34)
Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin's disease. (1973) (34)
Clinical aspects of drug resistance. (1986) (34)
Variants of human dihydrofolate reductase with substitutions at leucine-22: effect on catalytic and inhibitor binding properties. (1996) (34)
Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. (1982) (34)
Interrelationships of vitamin B12 and folate in man. (1970) (34)
Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. (1998) (33)
DETERMINATIONS OF THE LEVELS OF SERUM FOLATE IN PATIENTS WITH CARCINOMA OF THE HEAD AND NECK TREATED WITH METHOTREXATE. (1964) (33)
Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. (1977) (33)
Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. (1995) (33)
Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. (1999) (33)
High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. (1987) (33)
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells (2015) (33)
Hematopoietic stem cell gene therapy with drug resistance genes: an update (2005) (32)
Enzymic preparations of radiolabeded (+)-L-5-methyltetrahydrofolate and (+)-L-5-formyltetrahydrofolate. (1971) (32)
Clinical use of methotrexate--with emphasis on use of high doses. (1981) (32)
Analysis of the 14;18 translocation in cutaneous lymphomas using the polymerase chain reaction (1992) (31)
Methotrexate and 5-fluorouracil in sequence in squamous head and neck cancer. (1983) (31)
Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier (2008) (30)
Combined modality therapy for advanced Hodgkin's disease: long-term followup data. (1982) (30)
Genetic transformation of murine bone marrow cells to methotrexate resistance. (1983) (29)
GROWTH RATE AND CELL KILL * (1971) (29)
Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells. (1987) (29)
Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines. (1979) (29)
Second Neoplasms in Patients With Hodgkin's Disease Following Combined Modality Therapy-The Yale Experience. (1986) (29)
Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. (1995) (29)
DISCUSSION PAPER: L‐ASPARAGINASE INDUCED ALTERATION OF AMETHOPTERIN (METHOTREXATE) ACTIVITY IN MOUSE LEUKEMIA L5178Y (1971) (28)
Polymerase chain reaction analysis of DNA from paraffin-embedded tissue. (1993) (28)
Retention behavior of pteroyl-oligo-γ-l-glutamates in reversed-phase chromatography (1979) (28)
Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification by affinity chromatography and ultraviolet difference spectrophotometric and circular dichroic studies. (1977) (28)
Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy (2003) (28)
ENZYMIC OXIDATION OF METHOTREXATE AND AMINOPTERIN. (1964) (28)
The usefulness of the lukes‐collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy (1982) (28)
Antitumor activity of a folate-cleaving enzyme, carboxypeptidase G 1 . (1972) (28)
Conformational polymorphisms of cRNA of T-cell-receptor genes as a clone-specific molecular marker for cutaneous lymphoma. (1993) (28)
Activation of tetrahydrofolate dehydrogenase by certain cations. (1962) (28)
Use of electroporation for high-molecular-weight DNA-mediated gene transfer. (1987) (28)
Chemotherapy of colorectal cancer: history and new themes. (1997) (28)
Improving the curability of acute leukemia: pharmacologic approaches. (1991) (28)
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity (2017) (27)
Localization of a human reduced folate carrier protein in the mitochondrial as well as the cell membrane of leukemia cells. (2001) (27)
Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells (1997) (27)
Impaired utilization of serum folate in pernicious anemia. A study with radiolabeled 5-methyltetrahydrofolate. (1972) (27)
Drugs Five Years Later: Azathioprine (1973) (27)
Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase. (1983) (27)
Quinazoline analogues of folic acid as inhibitors of thymidylate synthetase from bacterial and mammalian sources. (1979) (26)
Quantitative analysis of folylpolyglutamate synthetase gene expression in tumor tissues by the polymerase chain reaction: marked variation of expression among leukemia patients. (1994) (26)
Efficient Generation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood in Stroma-Free Liquid Culture (2010) (26)
Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience. (1986) (26)
Occurrence and significance of D-methotrexate as a contaminant of commercial methotrexate. (1984) (26)
Isolation of a homogeneous preparation of human thymidylate synthetase from HeLa cells. (1980) (26)
INTERACTION OF ORGANIC MERCURIAL COMPOUNDS WITH DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS. (1965) (26)
Enhanced Degradation of Dihydrofolate Reductase through Inhibition of NAD Kinase by Nicotinamide Analogs (2013) (26)
Natural resistance to methotrexate in human acute nonlymphocytic leukemia. (1977) (26)
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. (2004) (25)
Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. (1997) (25)
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment (2009) (25)
Combination chemotherapy for advanced breast cancer. Two regimens containing adriamycin (1978) (25)
A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. (1984) (25)
Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. (2004) (25)
Folate antagonists as chemotherapeutic agents (1971) (25)
In vitro methotrexate polyglutamate synthesis by rat liver folylpolyglutamate synthetase and inhibition by bromosulfophthalein. (1983) (25)
Inhibition of Growth of Leukemia Cells by Enzymic Folate Depletion (1971) (25)
Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. (1998) (24)
Biomodulation of 5-fluorouracil with antifolates. (1997) (24)
A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5‐fluorouracil and levamisole after resection of high risk colon cancer (1994) (24)
Effect of [3H]methotrexate impurities on apparent transport of methotrexate by a sensitive and resistant L1210 cell line. (1980) (24)
Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells. (1970) (24)
Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics (2018) (24)
Darinaparsin Inhibits Prostate Tumor–Initiating Cells and Du145 Xenografts and Is an Inhibitor of Hedgehog Signaling (2014) (23)
Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists. (1976) (23)
Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. (1987) (23)
Molecular therapies for colorectal cancer metastatic to the liver. (2002) (23)
Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors (1999) (23)
Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab (2012) (22)
Myeloprotection with drug-resistance genes. (2002) (22)
In vivo expression of a nonselected gene transferred into murine hematopoietic stem cells by electroporation. (1986) (22)
Clinical and pharmacological evaluation of triazinate in humans. (1976) (22)
Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. (1982) (22)
Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. (1994) (22)
Granulocyte-Colony Stimulating Factor (G-CSF) May Improve Disease Outcome in Elderly Patients with Diffuse Large Cell Lymphoma (DLCL) Treated with CHOP Chemotherapy (2000) (22)
Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy (2015) (22)
FOLATE METABOLISM IN METHOTREXATE-SENSITIVE AND -RESISTANT EHRLICH ASCITES CELLS. (1964) (22)
Establishment, characterization and drug sensitivity of four new human soft tissue sarcoma cell lines (1996) (22)
The role of methotrexate and dihydrofolate polyglutamates in the enhancement of fluorouracil action by methotrexate. (1981) (22)
[179] Separation and identification of folate coenzymes on DEAE-sephadex (1971) (22)
Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. (2002) (22)
Introduction of deoxyribonucleoside triphosphates into intact cells by electroporation. (1986) (22)
The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist. (1973) (22)
Quantification of folate metabolism using transient metabolic flux analysis (2015) (21)
Continuous infusion fluorouracil/leucovorin and bolus mitomycin‐C as a salvage regimen for patients with advanced colorectal cancer (1995) (21)
Role of Pemetrexed in Non-Small Cell Lung Cancer (2007) (21)
Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy. (1967) (21)
Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. (2001) (21)
COMPLEX FORMATION WITH DNA AND INHIBITION OF NUCLEIC ACID SYNTHESIS BY METHYLGLYOXAL BIS(GUANYLHYDRAZONE). (1965) (21)
Rapid development of resistance to antifolates in vitro: possible clinical implication. (1991) (21)
"Turning the tables"--making normal marrow resistant to chemotherapy. (1990) (21)
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum. (1986) (21)
Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. (2007) (20)
Folyl and Antifolyl Polyglutamates (1983) (20)
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors (2019) (20)
In cancer, all roads lead to NADPH. (2021) (20)
Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. (2003) (20)
Gene amplification and altered enzymes as mechanisms for the development of drug resistance. (1983) (20)
Chromosomal assignment of amplified genes in hydroxyurea-resistant hamster cells. (1987) (20)
Inhibition of activities of DNA polymerase α, β, γ, and reverse transcriptase of L1210 cells by phosphonoacetic acid (1978) (20)
Regulation of dihydrofolate reductase and other folate-requiring enzymes. (1968) (20)
LEVELS OF DIHYDROFOLATE REDUCTASE AND THE FORMATE-ACTIVATING ENZYME ACTIVITIES IN GUINEA PIG TISSUES BEFORE AND AFTER AMETHOPTERIN ADMINISTRATION. (1964) (20)
Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas. (1967) (19)
ANTIMETABOLITES IN THE CHEMOTHERAPY OF LEUKEMIA. (1963) (19)
Megaloblastic anaemia produced by drugs. (1976) (19)
Capillary electrophoresis of methotrexate polyglutamates and its application in evaluation of gamma-glutamyl hydrolase activity. (1997) (19)
Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells. (1987) (19)
Molecular Imaging Reveals Skeletal Engraftment Sites of Transplanted Bone Marrow Cells (2006) (19)
DISCUSSION PAPER: SOME BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF AMETHOPTERIN‐ALBUMIN * (1971) (19)
Molecular targets for epigenetic therapy of cancer. (2009) (18)
Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. (1993) (18)
Encyclopedia of cancer (2002) (18)
Expression of P-glycoprotein in normal muscle cells and myogenic tumors. (1992) (18)
Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene (2004) (18)
LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes. (2015) (18)
Cyclophosphamide, cytosine arabinoside and methotrexate versus cytosine arabinoside and thioguanine for acute non‐lymphocytic leukemia in adults (1980) (18)
Nutrients, vitamins and minerals as therapy (1979) (17)
First-inHuman Clinical Trial of Oral ONC 201 in Patients with Refractory Solid Tumors (2019) (17)
Myeloblastoma and acute myelogenous leukemia: Presentation with a cervical neuropathy and complete response to chemotherapy (1982) (17)
Parenteral methotrexate for psoriasis. (1968) (17)
p14ARF Expression Increases Dihydrofolate Reductase Degradation and Paradoxically Results in Resistance to Folate Antagonists in Cells with Nonfunctional p53 (2004) (17)
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction. (1989) (17)
Methotrexate resistant cells as targets for selective chemotherapy. (1985) (17)
Pharmacology of a new triazine antifolate in mice, rats, dogs, and monkeys. (1975) (17)
Effects of wild‐type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines (1999) (17)
Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM‐L (1973) (17)
Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-lymphoblast cell line, CCRF-CEM. (1986) (17)
Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity. (1992) (17)
Metastatic breast cancer: preliminary results with oral hormonal therapy. (1985) (16)
Increased activity of some folic acid enzyme systems in infectious mononucleosis. (1962) (16)
Methotrexate selection of long-term culture initiating cells following transduction of CD34+ cells with a retrovirus containing a mutated human dihydrofolate reductase gene (2002) (16)
Cox-2 : a new target for cancer prevention and treatment (2003) (16)
Malignant histiocytosis. Response to VP‐16‐213 and cytosine arabinoside (1984) (16)
The effective use of combined modality therapy for the treatment of patients with Hodgkin's disease who relapsed following radiotherapy (1983) (15)
Clinical pharmacology of methotrexate. (1982) (15)
Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. (2004) (15)
Thymidylate synthase as an oncogene? (2004) (15)
STIMULATION OF DIHYDROFOLATE REDUCTASE ACTIVITY BY p-CHLOROMERCURIBENZOATE. (1964) (15)
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2. (1989) (15)
Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy (2020) (15)
Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer (2013) (15)
Annual Review of Pharmacology (1967) (14)
Ab initio studies of aromatic-aromatic and aromatic-polar interactions in the binding of substrate and inhibitor to dihydrofolate reductase. (2009) (14)
Dihydrofolate reductase from the L1210 R murine lymphoma. Further studies on the binding of substrates and inhibitors to the enzyme. (1967) (14)
Adjuvant therapy of osteosarcoma. (1987) (14)
Effect of methionine deprivation on L5178Y murine leukemia cells in culture interference with the antineoplastic effect of methotrexate. (1976) (14)
Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates. (1993) (14)
A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. (1995) (14)
A mechanism of resistance to methotrexate. NADPH but not NADH stimulation of methotrexate binding to dihydrofolate reductase. (1983) (14)
Dihydrofolate reductase from mouse liver and spleen. Purification, properties and inhibition by substituted 2,4-diaminopyrimidines and 4,6-diaminotriazines. (1971) (14)
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. (1995) (14)
Potent inhibitory activity of trimethoxyquine (tmq), "nonclassical" 2,4, diaminoquinazoline, on mammalian dna synthesis. Abstr. (1977) (14)
Time and dose relationships for methotrexate (MTX), fluorouracil (FUra) and combinations of these drugs for maximum cell kill in human CCRF-CEM cells (1982) (14)
Sequence analysis of a human gene responsible for drug resistance: a rapid method for manual and automated direct sequencing of products generated by the polymerase chain reaction. (1989) (13)
Chemotherapy of skeletal metastases. (1976) (13)
High‐dose pulse chlorambucil. Effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma (1982) (13)
Drug resistance in acute leukemia. (1993) (13)
Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase. (1966) (13)
Dihydrofolate reductase from guinea pig liver and small intestine. (1966) (13)
Species-Specific Differences in Translational Regulation of Dihydrofolate Reductase (2009) (13)
Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts (2014) (13)
Deficiency of retinoblastoma protein leads to inappropriate S-phase entry , activation of E 2 F-responsive genes , and apoptosis ( tumor supressor gene / cell cycle control / programmed cell death ) (12)
Current studies of the folate antagonists in patients with acute leukemia. (1965) (12)
RNA metabolism of normal and leukemic leukocytes. II. Ribonuclease. (1967) (12)
Formation of 10-formylfolic acid, a potent inhibitor of dihydrofolate reductase, in rat liver slices incubated with folic acid. (1974) (12)
131-I-3'-iodoaminopterin: a gamma-labeled active-site-directed enzyme inhibitor. (1968) (12)
Symposium on immunosuppressive drugs. Folate antagonists: some biochemical and pharmacological considerations. (1967) (12)
Use of electroporation to study the cytotoxic effects of fluorodeoxyuridylate in intact cells. (1987) (12)
Isolation of a herpesvirus-specific DNA polymerase from tissues of an American patient with Burkitt lymphoma. (1978) (12)
Sites of Inhibition of DNA Synthesis by Kethoxal bis(Thiosemicarbazone) (1968) (12)
Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia. (1990) (12)
Interaction of 2-thio-5-fluoro-dUMP and 4-thio-5-fluoro-dUMP with mammalian normal and tumour and helminthic thymidylate synthases: influence of C(4)-substituents on specificity for enzyme inactivation. (1993) (12)
A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance (1994) (12)
A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts (2014) (12)
A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5‐fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue (1996) (11)
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats (2003) (11)
Presence of type C particles containing reverse transcriptase in L1210 leukemia. (1977) (11)
Third Myron Karon Memorial Lecture. Resistance of human tumors to cancer chemotherapeutic agents: an important research problem. (1978) (11)
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. (1987) (11)
Pretreatment of endometrial carcinoma cell lines with butyrate results in upregulation of Bax and correlates with potentiation of radiation induced cell kill. (2000) (11)
A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. (2012) (11)
Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. (1995) (11)
Ectopic Cushing's syndrome in cloacogenic carcinoma of the anal canal: a case demonstrating APUD characteristics. (1980) (11)
CHAPTER 8 – FOLIC ACID1a (1967) (10)
Possible hazards of working with cytotoxic agents: a review of the literature. (1981) (10)
Small Molecule Inhibitors that Disrupt the MTDH-SND1 Complex Suppress Breast Cancer Progression and Metastasis (2021) (10)
Improved purification of tetrahydrofolate dehydrogenase from L1210 leukemia by affinity chromatography. (1972) (10)
Blood levels of chemotherapeutic agents and clinical outcome. (1987) (10)
Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line. (1985) (10)
Karyotypic analysis of methotrexate-resistant and sensitive mouse L5178Y cells. (1981) (10)
Design and rationale for novel antifolates. (1987) (10)
Consensus report on combined radiotherapy and chemotherapy modalities in lung cancer. (1988) (10)
Inhibition of two human tumor cell lines by antimetabolites of coenzyme Q10. (1978) (10)
Inhibition of peptide chain initiation in Escherichia coli by hydroxylamine. Reaction of hydroxylamine with folate coenzymes. (1970) (10)
Medullary Vagal Effects of d-Lysergic Acid Diethylamide in the Decerebrate Cat (1963) (10)
Multiple messenger RNAs for dihydrofolate reductase. (1981) (10)
Inhibition of serine metabolism by tetrahydrohomofolate in L1210 mouse leukemia cells. (1981) (10)
Pretreatment hematocrit as an independent prognostic variable in Hodgkin's disease. (1986) (10)
Inhibition of dihydrofolate reductase. 3. 4.6-Diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine inhibition of bovine liver and mouse tumor enzymes. (1980) (10)
Therapeutic strategies targeting proteins that regulate folate and reduced folate transport. (1999) (10)
EGFP fluorescence as an indicator of cancer cells response to methotrexate. (2007) (9)
Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma (2009) (9)
A second target of benzamide riboside (2012) (9)
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. (1989) (9)
Keynote address—Adjuvant chemotherapy and cancer cure (1982) (9)
High-resolution imaging of bone precursor cells within the intact bone marrow cavity of living mice. (2005) (9)
Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. (2006) (9)
Systemic methotrexate toxicity. A pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. (1976) (9)
Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. (1997) (9)
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine. (1985) (9)
Antibody to dihydrofolate reductase from a methotrexate-resistant subline of the L1210 lymphoma. (1969) (8)
3′,5′-Ditritiomethotrexate as a Granulocyte Label (1965) (8)
Leucovorin rescue revisited. (1990) (8)
Folate Antagonists: Toward Improving the Therapeutic Index and Development of New Analogs (1990) (8)
The basis for intrinsic drug resistance or sensitivity to methotrexate. (1989) (8)
Activated matriptase as a target to treat breast cancer with a drug conjugate (2018) (8)
Sequence-dependent synergism between dichloromethotrexate and 5-fluorouracil in a human colon carcinoma cell line. (1983) (8)
Comparison of methotrexate resistance conferred by a mutated dihydrofolate reductase (DHFR) cDNA in two different retroviral vectors (2000) (8)
A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. (2012) (8)
E2F-1 as an anticancer drug target (2011) (8)
Rapid and sensitive molecular subtyping of microorganisms in clinical specimens (1993) (8)
Polyglutamate forms of folate: natural occurrence and role as substrates in mammalian cells. (1976) (8)
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer (2004) (8)
Mutations leading to antifolate resistance in Chinese hamster ovary cells after exposure to the alkylating agent ethylmethanesulfonate. (1993) (8)
Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells. (1988) (8)
Clinical studies with LSD-25 and two substances related to serotonin. (1960) (8)
Drug Resistance: New Approaches to Treatment (1986) (8)
mTOR inhibition leads to increased sensitivity to methotrexate (2005) (8)
Rationale for the selection of chemotherapeutic agents. (1969) (7)
DISCUSSION PAPER: KINETIC INVESTIGATION OF THE REACTION MECHANISM OF DIHYDROFOLATE REDUCTASE FROM L1210 CELLS * (1971) (7)
Comparative effects of folate antagonists versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells. (1977) (7)
Cholinesterase, dlysergic acid diethylamide, and 2-bromolysergic acid diethylamide. (1959) (7)
Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1. (1979) (7)
Immobilized Enzymes in Tubes and Hollow Fibers for Clinical Applications (1978) (7)
Cis-Platinum Chemotherapy in Head and Neck Cancers (1978) (7)
Enzymic preparations of radiolabeled +-L-5-methyltetrahydrofolate and +-L-formyltetrahydrofolate. (1980) (7)
Detection of a single base mutation in the human dihydrofolate reductase gene from a methotrexate-resistant cell line using the polymerase chain reaction. (1989) (7)
Modeling and antitumor studies of a modified L–penetratin peptide targeting E2F in lung cancer and prostate cancer (2018) (7)
Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. 1978. (1992) (7)
Enzymes of the thymidylate cycle as targets for chemotherapeutic agents: mechanisms of resistance. (1992) (7)
Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer (1996) (6)
Prediction of antifolate efficacy in a rat sarcoma model (1991) (6)
Lack of expression of MTAP in uncommon T-cell lymphomas. (2012) (6)
22 – METHOTREXATE: CLINICAL PHARMACOLOGY AND THERAPEUTIC APPLICATION (1981) (6)
Methotrexate: historical aspects (2000) (6)
Manual and automated direct sequencing of product generated by the polymerase chain reaction. (1993) (6)
Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate. (1976) (6)
The effects of 5-hydroxytryptophan (a serotonin precursor) in schizophrenic patients. (1960) (6)
Enhancement of fluoropyrimidine inhibition of cell growth by leucovorin and deoxynucleosides in a human squamous cell carcinoma cell line. (1989) (6)
Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate. (1989) (6)
Detection of clonal T‐cell populations in gastrointestinal lymphomas by analysis of cRNA conformational polymorphisms of rearranged T‐cell‐receptor‐gamma genes (1994) (6)
Combination chemotherapy of sarcoma 180 with methotrexate and bleomycin. (1973) (6)
Effect of codon 22 mutations on substrate and inhibitor binding for human dihydrofolate reductase. (1993) (6)
2D Magnetic Sensor Array for Real-time Cell Tracking and Multi-site Detection with Increased Robustness and Flow-rate (2019) (6)
Transfer of drug resistance genes into hematopoietic stem cells for marrow protection. (2008) (6)
Immobilized carboxypeptidase G1 in methotrexate removal. (1978) (6)
Gene therapy--the challenge for the future. (1996) (6)
Failure of leucovorin "rescue" in methotrexate treatment of psoriasis. (1970) (6)
The potential for chemotherapy and hyperthermia. (1984) (6)
Differential efficacy of trimetrexate (2,4-diamino-6-methyl-(3,4,5-trimethoxyanilino)methyl) quinazoline, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro (1985) (6)
Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037). (1973) (6)
18 – METHOTREXATE: MOLECULAR PHARMACOLOGY (1981) (6)
Synthesis of 2,4-Diaminopteridines with Bulky Lipophilic Groups at the 6-Position as Inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mammalian Dihydrofolate Reductase (1997) (6)
Isolation and functional effects of monoclonal antibodies binding to thymidylate synthase. (1985) (6)
Molecular detection and characterization of clonal cell populations in acute lymphocytic leukemia by analysis of conformational polymorphisms of cRNA molecules of rearranged T-cell-receptor-gamma and immunoglobulin heavy-chain genes. (1994) (5)
Landmark Study: The Relation of Solar Radiation to Cancer Mortality in North America. (2016) (5)
Quantitative determination of the ratio of mutated to normal ras genes in the blood of leukemia patients by allele-specific PCR. (1994) (5)
Sequence analysis of polymerase chain reaction amplified t(14;18) chromosomal breakpoints in formalin fixed, paraffin wax embedded follicular lymphoma. (1992) (5)
Variation of dihydrofolate reductase activity in mammalian cells in vitro (1969) (5)
A fluorometric assay for dihydrofolate reductase. (1977) (5)
Purification and Properties of Carboxypeptidase G , * (2003) (5)
Clinical evaluation of local hyperthermia by focused ultrasound (abstract) (1982) (5)
Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide , and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma (2017) (5)
Phase I–II trial of mitoxantrone in acute leukemia: an interim report (2004) (5)
Splenectomy in Hodgkin's disease: No therapeutic benefit (1982) (5)
Trimetrexate: overall clinical results. (1988) (5)
Thymidylate synthase inhibition in cells with arrested DNA synthesis is not due to an allosteric interaction in the replitase complex. (1985) (5)
Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. (2019) (5)
Antitumor drug interactions: additional data. (1976) (4)
Recent Progress in Molecular Dynamics Simulations of Dihydrofolate Reductase (2012) (4)
Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines. (1999) (4)
A comparison of the inhibition of bovine and murine leukemia dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(3-X-phenyl)-s-triazines. (1981) (4)
Drug Resistance In The Treatment of Cancer: Resistance mechanisms to antimetabolites (1998) (4)
Metabolic alterations accompanying amethopterin resistance in the ehrlich ascites carcinoma. Abstr. (1962) (4)
Transport of 5-methyltetrahydrofolate by l1210 mouse leukemia cells. Abstr. (1969) (4)
Folate and anti-folate transport in mammalian cells. (1980) (4)
Impaired methotrexate polyglutamylation in a human leukemia cell line resistant to short-term, high-dose methotrexate. (1988) (4)
A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1. (2015) (4)
Action of zoxazolamine upon spinal segmental reflexes. (1958) (4)
Antagonism of the antineoplastic effect of methotrexate (mtx) by l-asparaginase(asn'ase) or l-asparagine(asn) deprivation. Abstr. (1970) (4)
Uptake and metabolism of N 5 -formyltetrahydrofolate by L1210 leukemia cells. (1972) (4)
Studies on the Substrate Specificity of Mammalian Folylpolyglutamate Synthetase (1983) (4)
Chemoprotection by transfer of resistance genes. (2009) (4)
High-performance liquid chromatographic method for the simultaneous measurement of floxuridine and fluorouracil in human body fluids. (1991) (4)
Abstract LB-209: D2-like dopamine receptor antagonism by ONC201 identified by confluence of computational, receptor binding, and clinical studies (2016) (3)
Vriation of dihydrofolate reductase activity in mammalian cells in vitro. (1969) (3)
Development of an amphotropic, high-titer retrovirus vector expressing the dihydrofolate reductase gene and conferring methotrexate resistance. (1986) (3)
Chemotherapy of testicular cancer at Yale: 1976-1982. (1985) (3)
Modulation of 5-fluorouracil/leucovorin by trimetrexate--did it work? (2002) (3)
Combined use of ACTH, cortisone and chemotherapy in tuberculous and non-tuberculous meningitis (1952) (3)
Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors. (1975) (3)
Advances in Brief Role of E 2 F-1 in Chemosensitivity 1 (2006) (3)
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma (2019) (3)
Absence of retinoblastoma protein mediates intrinsic resistance to antimetabolites in human sarcoma cell lines (1994) (3)
Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma. (1991) (3)
The treatment of disseminated vasculitis with methotrexate (1976) (3)
Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression (2012) (3)
Phase II Study of Pulse 5‐Fluoro‐2′‐Deoxyuridine and Leucovorin in Advanced Colorectal Cancer Patients Previously Treated with Chemotherapy (1992) (3)
Mechanisms of drug resistance in human leukemia. (1985) (3)
Activation and inhibition of carboxypeptidase G1 by divalent cations (1972) (3)
Abstract 223: Generation of single cell-derived normal, benign and cancer mini-prostates from primary patient-derived tissues (2015) (3)
Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate. (1999) (3)
Abstract 2596: Targeted delivery of doxorubicin conjugated with anti-matriptase antibody to treat multiple myeloma (2010) (3)
Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients (2004) (3)
Inactivation by mouse serum of a tightly bound inhibitor of dihydrofolate reductase. (1970) (3)
Bleomycin, adriamycin, CCNU and oncovin combination (BACO) in advanced and recurrent lymphomas (1977) (3)
Examination of the Reduced Affinity of the Thymidylate Synthase G52S Mutation for FdUMP by Ab Initio and Semi-empirical Studies (2001) (3)
A method to detect transfected chloramphenicol acetyltransferase gene expression in intact animals. (1988) (3)
MTHFD2- a new twist? (2016) (3)
Adjuvant chemotherapy and cancer cure. (1982) (3)
Sequential methotrexate and 5-fluorouracil: Biochemical pharmacology and therapeutic use (1983) (3)
Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin (2021) (3)
Effects of certain vitamins and histamines on the LSD psychosis. (1959) (3)
Approaches to drug selectivity in cancer therapy on the basis of differences between membranes of normal vs. neoplastic cells. (1980) (2)
Ab initio studies of some amino acid residue complexes with 4-mercaptopyridine as a model for thymitaq (AG337), an inhibitor of thymidylate synthase. (1999) (2)
Lymphoma ABT-199 , a BH 3 Mimetic That Specifically Targets Bcl-2 , Enhances the Antitumor Activity of Chemotherapy , Bortezomib , and JQ 1 in “ Double Hit ” Lymphoma cells (2)
Recovering 3D tumor locations from 2D bioluminescence images and registration with CT images (2006) (2)
Clinical and pharmacological studies of the folate antagonist, triazinate (Baker's antifol, TZT) (1974) (2)
Enhanced therapeutic index with hyperthermia. Abstr. (1979) (2)
Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control. (2019) (2)
Current concepts in the treatment of adult leukemia. (1974) (2)
Abstract 4279: Targeting Bmi1 in human prostate tumor initiating cells (2010) (2)
E2F and Cancer Chemotherapy (2002) (2)
Translational Modulation of Proteins Expressed from Bicistronic Vectors (2009) (2)
MULTIVARIATE ANALYSIS AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS. INHIBITION OF DIHYDROFOLATE REDUCTASE AND THYMIDYLATE SYNTHETASE BY QUINAZOLINES (1979) (2)
Chemotherapy of Squamous Head and Neck Cancer (1984) (2)
Theoretic and practical considerations of the combined use of ACTH, cortisone and chemotherapy in the management of generalized peritonitis (1952) (2)
RESISTANCE TO FOLIC ACID ANTAGONISTS - CLINICAL ASPECTS* (1975) (2)
Identification of mutations by RNA conformational polymorphism "bar code" analysis. (1995) (2)
Barriers and strategies for effective chemotherapy. (1992) (2)
Chapter 48 – Cancer Therapeutics (2008) (2)
Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice (2012) (2)
Inhibition of activities of DNA polymerase alpha, beta, gamma, and reverse transcriptase of L1210 cells by phosphonoacetic acid. (1978) (2)
Dihydrofolate reductase as an oncogene: a microRNA binding site SNP leads to cellular transformation and drug resistance (2008) (2)
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines. (2000) (2)
The multidrug resistance phenotype (1985) (2)
Correlate with Levels of Thymidylate Synthase Colon Cancer As Compared with Hepatic Metastasis and Levels of E 2 F-1 Expression Are Higher in Lung Metastasis of Updated (2000) (2)
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. (2018) (2)
PREPARATION OF NORMAL AND MALIGNANT HUMAN CELLS FOR STUDY OF RESISTANCE. (1964) (2)
Uptake of 5-formyltetrahydrofolate by l1210 mouse leukemia cells and its effect on uptake of methotrexate. Abstr. (1969) (2)
First-in-human trial of ONC201 in patients with refractory solid tumors. (2016) (2)
Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys. (1975) (2)
Abstract 5393: Regression of a human T-cell leukemia lacking the methylthioadenosine phosphorylase (MTAP) gene without toxicity of 6-thioguanine (6TG) by pretreatment with methylthioadenosine (MTA) (2010) (1)
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase. (1983) (1)
Effects of steroids, folate deprivation and protein deprivation upon tetrahydrofolate dehydrogenase levels in mammalian tissues. (1973) (1)
Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in "double hit" lymphoma. (2014) (1)
Recent developments in chemotherapy of malignancy. (1975) (1)
Antimetabolites in combination with other drugs improve therapy of diffuse aggressive non-Hodgkin's lymphoma. (1986) (1)
Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise? (2008) (1)
46 – Cancer Therapeutics (2015) (1)
Approaches to selectivity in cancer chemotherapy. (1976) (1)
Assessment of patient response to targeted cancer therapy using multi-frequency impedance cytometry and unsupervised machine learning (2018) (1)
Activity of 5, 10-Methenyltetrahydrofolate Synthetase in Rat Tissues and in Tumor Cell Lines (1990) (1)
Are we getting closer to using methotrexate in an optimal manner? (2011) (1)
Prevention of methotrexate (mtx) toxicity by carboxypeptidase g1 (cpd g1). Abstr. (1972) (1)
Folates and Cancer Chemotherapy (1983) (1)
Modulation of fluoropyrimidines by pretreatment with antifolates or folinic acid (leucovorin). (1990) (1)
The role of methotrexate in the chemotherapy of gestational trophoblastic neoplasms. (1984) (1)
Modulation of fluorouracil by methotrexate. (1991) (1)
Abstract 2756: Phase I trial of 2-deoxyglucose for treatment of advanced solid tumors and hormone refractory prostate cancer: A pharmacokinetics (PK) assessment (2010) (1)
Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination (2015) (1)
New approaches to chemotherapy of leukemia and epidermoid carcinoma. (1967) (1)
Synthesis and evaluation of 2,4-diaminoquinazoline antifolates with activity against methotrexate-resistant human tumor cells. (1984) (1)
A 3′ UTR Single Nucleotide Polymorphism 829C→T in Dihydrofolate Reductase Gene Results in an Increase in DHFR Protein Level and MTX Resistance. (2004) (1)
Chemotherapy for colorectal cancer. (1994) (1)
Review of mechanisms of cell resistance to therapy in lung cancer. (1988) (1)
Studies with a 2,4-diamino-5-chloro-quinazoline antifolate: in vitro and invivo correlates in normal and lymphosarcoma dogs. (1971) (1)
The evolving role of antifolates in metastatic colorectal cancer (1997) (1)
Disparate sensitivity of prostate cancer cell lines to antifolates (2006) (1)
The Yale combination chemotherapy program for advanced Hodgkin's disease. A preliminary report. (1970) (1)
Further studies on the increase in thymidylate synthetase (TS) and thymidine kinase (TK) in RPMI 4265 human lymphoid cells in culture after exposure to folate antagonists (1974) (1)
Sequential methotrexate and fluorouracil in colon cancer. (1992) (1)
Electrophoretic assay of folylpolyglutamate synthetase activity. (1981) (1)
Cell proliferation and tissue remodeling are major determinants of cancer metabolism and the response to drugs targeting metabolism (2014) (1)
Hazards of working with cytotoxic agents--a response. (1982) (1)
Monitoring methotrexate levels in osteosarcoma. (1998) (1)
Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). (2017) (1)
Absorption of leucovorin (NSC-3590) from a "mouthwash". (1975) (1)
638 Pharmacodynamics of apilidinR (APL) in experimental models of haematological malignancies (HAMA) (2003) (1)
‘Tomudex’ (raltitrexed) plus 5-fluorouracil: a promising option for the treatment of patients with metastatic colorectal cancer (1999) (1)
Imipridone (ONC201) and Radiation Therapy Combination Shows Promise in Breast Cancer Treatment (2018) (1)
Chemotherapeutic approaches to advanced carcinoma of the larynx. (1975) (1)
Abstract 4543: Targeting the NADPH binding site of dihydrofolate reductase for cancer therapy (2010) (1)
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates (2013) (1)
Pharmacology and Therapeutics: A Textbook for Students and Practitioners of Medicine and Its Allied Professions (1971) (1)
Implantable pumps--opportunities for improved therapy of malignant disease. (1983) (1)
Combination Radiation Therapy and Imipridone ONC201 for the Treatment of Solid Tumors (2017) (1)
Combination vs. combination sequential non hormonal chemotherapy in advanced breast cancer (1976) (1)
Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy (2017) (1)
A methotrexate resistant subline of l1210 characterized by impaired transport of methotrexate, but not 5-methyl tetra- hydrofolate. Abstr. (1978) (1)
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications (1994) (1)
Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC). (2016) (1)
Long-term remissions in lymphoblastic lymphoma. (1983) (1)
Clinical and PharmacologicalEvaluationof Triazinate in Humans1 (1976) (1)
Letter: Azathioprine and allopurinol. (1974) (1)
Translational upregulation of dihydrofolate reductase by methotrexate is an intrinsic mechanism of resistance (2005) (1)
Current status of trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. (1989) (1)
High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer. (1996) (1)
Pre-clinical trials of a new triazine antifolate, nsc 139105. Abstr. (1973) (1)
Intermediary metabolic patterns in murine and human leukemic cells. Effects of methotrexate treatment (1973) (0)
Uptake studies with Aplidin, a marine depsipeptide under clinical development (2007) (0)
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas (1991) (0)
Alan Sartorelli: A Personal Remembrance (2015) (0)
Drug Resistant Cells as Targets for Chemotherapeutic Agents (1989) (0)
Amplification of dihydrofolate reductase (dhfr) genes in an l5178y line resistant to methotrexate (mtx). Abstr. (1979) (0)
Combined use of ACTH, cortisone and chemotherapy in pulmonary and genitourinary tuberculosis (1952) (0)
Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells (2014) (0)
Do we need a new strategy to treat metastatic breast cancer? (1999) (0)
Abstract 843: Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination (2014) (0)
Hepatocellular carcinoma. Current concepts of its etiology and a proposal for a clinical staging system. (1987) (0)
Mutation at hydrophobic residues in dihydrofolate reductase (1990) (0)
Irradiated Third Party Peripheral Blood Mononuclear Cells Enhance Umbilical Cord Blood Engraftment. (2009) (0)
Studies of a novel modified E2F-targeted peptide with activity against castration-resistant prostate cancer. (2017) (0)
Abstract B211: Cellular zinc homeostatic mechanisms function as an off switch for zinc metallochaperone-mediated reactivation of mutant p53 (2018) (0)
Development of Sensitive Assays to Detect Antifolate Resistance in Leukemia Blasts (1992) (0)
Inhibition of activities of dna polymerases alpha, beta, gamma and reverse transcriptase of a lymphoid leukemia cell line, l1210 by phosphonoacetic acid. Abstr. (1977) (0)
METHYLTHIOADENOSINE PHOSPHORYLASE (MTAP) GENE DELETION IN OSTEOSARCOMA (2001) (0)
Volume 21 Acknowledgments (2016) (0)
Evaluation of Dose-Intense Ifosfamide, with and Without Edatrexate, in Adults with Sarcoma (1999) (0)
Accelerated R-COP:A Pilot Study for the Treatment of Follicular Lymphoma. (2005) (0)
Design, synthesis, and evaluation of potential carbamate prodrugs of 5′-methylthioadenosine (MTA) (2021) (0)
Abstract A61: Darinasparsin (Z101) inhibits prostate cancer stem cells via inhibition of hedgehog signaling. (2011) (0)
Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer (2020) (0)
c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated (2002) (0)
BIOCHEMICAL REACTORS FOR POTENTIAL USE IN CANCER CHEMOTHERAPY. (1976) (0)
PSMA activation of antifolate prodrugs for treatment of prostate cancer (2007) (0)
Some enzyme changes of clinical importance in leukemia. (1968) (0)
Drug-Induced Blood Disorders (1976) (0)
Abstract 1803: Lethal synthesis: Potent anticancer activity of a glycine uptake inhibitor in tumor cells with mitochondrial methylenetetrahydrofolate dehydrogenase (MTHFD2) knocked down (2022) (0)
Synthesis and evaluation of lipid soluble "non-classical" quinazoline antifolates. Abstr. (1983) (0)
Antagonists in Man * (2006) (0)
Decreased Reduced Folate Carrier Expression Resistance in Acute Lymphocytic Leukemia and Is Associated With Defective Transport Is a Common Mechanism of Acquired Methotrexate (1997) (0)
Alan Sartorelli: A Personal Remembrance. (2015) (0)
Abstract 3981: Enhancement of the anticancer activity of methylenetetrahydrofolate dehydrogenase knockdown by folate depletion with carboxypeptidase G2 (2018) (0)
Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. (2016) (0)
Medical oncology: a sub-specialty that has come of age. (1979) (0)
Abstract 2535: Synergistic anti-tumor activity of the Notch gamma secretase inhibitor BMS-906024 and paclitaxel in the treatment of lung adenocarcinoma (2015) (0)
Successful Expansion of Umbilical Cord Blood Cells as a Source of Hematopoietic Progenitors for Adult Transplantation. (2004) (0)
Abstract 4615: Development of an antibody-drug conjugate with broad anticancer activity (2017) (0)
Functional impairments in methotrexate transport are common in osteosarcoma tumor samples (2001) (0)
Abstract 5213: A modified L-penetratin peptide targeting e2f-1, 2 and 3 is effective in combination with cisplatin or pemetrexed against prostate and lung cancer cell lines (2019) (0)
Referee acknowledgement for 2017 (2018) (0)
Altered thymidylate synthase (TS) from human colon tumor (HCT-8) cells resistant to 5-fluoro-2'-deoxyuridine (FdUrd) (1984) (0)
Ab initio studies of 2,4-diamino triazine and its complexes with ligands: a model for inhibitor-active site interactions of dihydrofolate reductase. (1994) (0)
Basic biology of malignancy (1980) (0)
Lack of Mutation of L1210 Thymidylate Synthase with Altered Sensitivity to FdUMP Inhibition (2002) (0)
Abstract 5689: Anti-E2F-1 PEGylated liposomal encapsulated peptide regresses human small cell lung cancer & lymphoma xenografts (2012) (0)
3-dimensional multi-modality non-invasive imaging of the bone marrow engraftment model (2004) (0)
Abstract 1237: Antitumor studies of an E2f1 promoter sequence binding peptide - penetratin conjugate as a molecule targeting E2f in prostate cancer (2015) (0)
2018 Reviewer Acknowledgment (2019) (0)
Author and Subject Index (1999) (0)
Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy (2015) (0)
Thymidylate S ynthase E xpression i n H epatic T umors I s a Predictor o f S urvival a nd P rogression i n P atients W ith Resectable M etastatic C olorectal C ancer (2003) (0)
Aplidin potentiates antitumor effect of gemcitabine in vitro as well as in vivo (2007) (0)
Association of lack of uridine monophophosphate kinase expression in tumor samples from colorectal cancer patients with clinical resistance to 5-Fluorouracil (2004) (0)
Commentary (Bertino): New Antifolates in Clinical Development (1995) (0)
Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy (2020) (0)
The Journal thanks the following consultants who, in addition to the members of the Editorial Board, gave their time to review manuscripts submitted in 1980. (1980) (0)
Resistance to Antifolates (2003) (0)
2018 Reviewer Acknowledgment (2019) (0)
Carboxypeptidase g1(g1). A new approach to anti-folate chemotherapy. Abstr. (1971) (0)
Prediction of methotrexate responsiveness of tumors in man. (1971) (0)
A novel immunoassay to quantify paclitaxel in plasma using monoclonal antibody-coated nanoparticles. (2011) (0)
A Novel Antibody-Toxin Congujate to Treat Mantle Cell Lymphoma (2017) (0)
Drugs Five Years Later (2020) (0)
Quantification of folate metabolism using transient metabolic flux analysis (2015) (0)
2017 Reviewer Acknowledgment (2018) (0)
Inhibition of DNA Synthesis in Normal and Malignant Human Cells by Triazinate ( Baker ' s Antifol ) and Methotrexate 1 (2006) (0)
Effect of Phosphonoacetate on Cellular and Viral DNA Polymerases (1979) (0)
Activation and inhibition of carboxypeptidase G 1 by divalent cations. (1972) (0)
Mutations in the Human Dihydrofolate Reductase (1986) (0)
Abstract 996: Receptor tyrosine kinase AXL is upregulated in metformin resistant prostate cancer cells. (2013) (0)
Inadvertent Drug Interactions with MTX (2003) (0)
Strategies to Overcome Resistance to MTX Using New (or Older) AntiFols (2003) (0)
Mechanisms of Methotrexate Resistance in Osteosarcoma 1 (1999) (0)
MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998. (1999) (0)
Targeting signal transduction (2001) (0)
Synthesis of epothilones, their intermediates and analog connections (1999) (0)
Effects of methotrexate on cells from rapidly growing and from resting cultures (1969) (0)
Pharmacokinetics of MTX (2003) (0)
Translational regulation of dihydrofolate reductase IDENTIFICATION OF AMINO ACIDS REQUIRED FOR THE FUNCTIONAL UPREGULATION OF HUMAN DIHYDROFOLATE REDUCTASE PROTEIN IN RESPONSE TO ANTIFOLATE TREATMENT (2005) (0)
A Novel siRNA-Based Approach to Study Mechanisms of Resistance/Action of a New Drug in Treatment of Breast Cancer. Addendum (2006) (0)
Abstract 214: Androgen resistance in prostate cancer is associated with an enrichment of stem-like cells (2014) (0)
Aplidine for treatment of multiple myeloma (2004) (0)
Vector encoding the human globulin gene and use thereof in the treatment of hemoglobinopathies (2002) (0)
The pharmacology of immunosuppressive agents. (1970) (0)
Is there life after methotrexate? (2002) (0)
Aminopterin--iodine-131, a folate antagonist. Preparation, distribution, and scanning in man. (1967) (0)
Recovering 3 D tumor locations from 2 D bioluminescence images (2006) (0)
JOHNS , HOLLINGSWORTH , CASHMORE , PLENDERLEITH , AND BERTINO (2013) (0)
Molecular Biologyof Cancer: Implications for Prevention and Therapyâ€”Third Joint Meeting of the American Associationfor Cancer Research and the Japanese Cancer Association (2006) (0)
Running Title : Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy Corresponding Author (2015) (0)
2038 Autologous bone marrow transplantation following high-dose chemotherapy with or without accelerated hyperfractionated total lymphoid irradiation for patients with refractory or relapsed Hodgkin's disease (1995) (0)
Toward point-of-care assessment of patient response: a portable tool for rapidly assessing cancer drug efficacy using multifrequency impedance cytometry and supervised machine learning (2019) (0)
Abstract 4208: The castrate resistant PC-3 cell line with neuroendocrine features is enriched in tumor initiating cells and is resistant to enzalutamide and abiraterone but sensitive to antimetabolites (2015) (0)
Abstract 5536: NAD+ Kinase inhibition synergizes with ROS-inducing chemotherapies. (2013) (0)
Resistance to methotrexate in experimental models and in patients (1990) (0)
Tumors Pathway: A New Determinant of Methotrexate Selectivity in Serine - Overexpression of the Mitochondrial Folate and Glycine (2013) (0)
Reviewers of the Journal of Chemotherapy (2010) (0)
Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells (1998) (0)
Pharmacology of dichloromethotrexate. (1989) (0)
Identification and Characterization of Monoclonal Lymphoid Populations by Analysis of Complementary RNA of Clonespecific DNA Sequences (1994) (0)
Abstract 2759: Validated liquid chromatography-mass spectrometry assay for determination of busulfan: Application to clinical pharmacokinetics studies (2010) (0)
Management of Colorectal Cancer Defining the Role of Raltitrexed (2001) (0)
Organization of the methotrexate resistant mouse L5178YR dihydrofolate reductase gene and transformation of human HCT-8 cells by this gene. (1981) (0)
Referee acknowledgement for 2019 (2020) (0)
Abstract A266: Leucovorin rescue of high dose pralatrexate in mesothelioma xenografts. (2013) (0)
Reductase by the folic acid antagonists. Abstr. (1963) (0)
Introduction to the symposium (1983) (0)
INTRODUCTION (1971) (0)
Cell proliferation and tissue remodeling are major determinants of cancer metabolism and the response to drugs targeting metabolism (2014) (0)
A . Dye Exclusion Test Using Trypan Blue (2007) (0)
[Mechanisms of resistance to methotrexate]. (1991) (0)
Abstract PR06: Functional prioritization of rare gene aberration drivers of cancer (2015) (0)
Vitamin b12 and transcobalamin ii stimulate utilization of 5-methyl- tetrahydrofolic acid by l5178y mouse leukemia cells. Abstr. (1972) (0)
Mechanism of Fluorouracil Resistance Decreased Folylpolyglutamate Synthetase Expression : A Novel Updated (2006) (0)
Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease. (1971) (0)
I point mutations in human ition polymorphism ! (2005) (0)
Mitochondrial as Well as the Cell Membrane of Leukemia Cells Localization of a Human Reduced Folate Carrier Protein in the Updated (2001) (0)
Abstract 3548: Selective targeting of pancreatic tumors lacking methylthioadenosine phosphorylase (MTAP) (2011) (0)
The reaction mechanism of dihydrofolate reductase from l1210 cells. Abstr. (1969) (0)
Depletion 1 Pyrimidine Depletion Can Markedly Enhance Cancer Therapy : Fresh Insight for a New Approach 1 (2000) (0)
Salute to Our Reviewers. (2016) (0)
Tissue Sarcomas Mechanisms of Natural Resistance to Antifolates in Human Soft Updated (2006) (0)
Abstract 2673: In silico design of E2F1 mimics as potential anticancer agents (2010) (0)
Recent developments in chemotherapy of malignancy (1975) (0)
Preclinical Investigations Demonstrate Effectiveness of Aplidin in Acute Leukemias and Lymphomas and Provide the Basis for Further Clinical Studies. (2004) (0)
Comprehensive care of adult acute leukemia. (1972) (0)

This paper list is powered by the following services:

Other Resources About Joseph R. Bertino

en.wikipedia.org

What Schools Are Affiliated With Joseph R. Bertino?

Joseph R. Bertino is affiliated with the following schools:

Joseph R. Bertino's Academic­Influence.com Rankings

Joseph R. Bertino's Degrees

Why Is Joseph R. Bertino Influential?

Joseph R. Bertino's Published Works

Published Works

Other Resources About Joseph R. Bertino

What Schools Are Affiliated With Joseph R. Bertino?

Joseph R. Bertino's AcademicInfluence.com Rankings